Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways
Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.
You may also be interested in...
Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program
The Reagan-Udall Foundation has established an organizing committee to help inform the design and structure of what its Innovation in Medical Evidence Development and Surveillance program’s post-market research methods should look like and develop the IMEDS charter.
Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter
Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.
TB Regimen Could Pave Way For More FDA Involvement In Neglected Tropical Diseases
TB Alliance plans to seek FDA approval for its treatment regimen, which is beginning a Phase IIb trial, as the agency looks to respond to calls for a clearer and quicker pathway for NTD drugs.